Methods: In this prospective study, patients with gout receiving urate lowering therapy with benzbromarone were assigned to two groups, a renal underexcretion and an unclassified type. The primary ...

OBJECTIVES To study the efficacy of allopurinol and benzbromarone to reduce serum urate concentrations in patients with primary chronic gout. METHODS Prospective, parallel, open study of 86 ...

Despite dotinurad’s prominence today, the 50-year history of URAT1 inhibitors has been marked by setbacks, particularly concerning safety. The first URAT1 inhibitor, benzbromarone, was approved in ...

Choi notes that many of these lifestyle changes will not only reduce uric acid levels and the risk of recurrent gout but will also improve the health status of those with comorbidities ...

Eligible for inclusion were adult patients (≥18 years) with microscopically verified gout who initiated or increased ULT (allopurinol, benzbromarone or febuxostat). For the latter group, crystal ...

This measure strongly correlated with intensity of urate lowering (r=−0.62, p<0.05). Compared with allopurinol alone, benzbromarone alone or combination treatment of benzbromarone and allopurinol also ...

With the changes in modern life, hyperuricemia (HUA) has become a serious universal health issue, leading to rising morbidity and mortality. Characterized by elevated levels of UA, HUA has become an ...

Objective Verinurad (RDEA3170) is a high-affinity, selective URAT1 inhibitor in development for treating gout and asymptomatic hyperuricaemia. This study evaluated the pharmacodynamics, ...